Joaquin Duato has spent most of his professional life inside Johnson & Johnson, progressing from a position at its Spanish pharmaceutical subsidiary to the company’s highest executive roles. He joined the organization in 1989, worked across different regions and business sectors, became CEO in January 2022 and added the chairmanship one year later.
His advancement was built on assignments spanning several regions, business sectors and operational functions. Duato’s assignments covered pharmaceuticals, consumer health, medical technology, supply-chain operations and information technology. More recently, he has directed attention toward medical innovation, complex diseases and the potential use of artificial intelligence in healthcare.
| Category | Details |
|---|---|
| Current position | Chairman and CEO of Johnson & Johnson |
| Citizenship | Spain and the United States |
| Education | ESADE and Thunderbird School of Global Management |
| Initial company | Janssen-Farmaceutica in Spain |
| Business experience | Innovative Medicine, MedTech and international operations |
| Company tenure | Nearly four decades at Johnson & Johnson |
| Public interests | Medical innovation, cancer research, cognitive health and AI |
His International Education and Spanish-American Background
Duato’s official Johnson & Johnson biography identifies him as a dual citizen of Spain and the United States. Reputable reporting connects his early years with Valencia, Spain, although the company’s current profile does not provide a precise birthplace.
His graduate education prepared him for an international business career. He earned a Master of Business Administration from ESADE in Barcelona and a Master of International Management from Thunderbird School of Global Management in Arizona. Official records do not provide the years in which he completed those degrees.
Professional assignments across multiple countries followed that combination of Spanish and American education. Duato later told the U.S. Senate that his experience in both Europe and the United States helped him understand the complexities of healthcare development and delivery in different markets.
His First Johnson & Johnson Application Ended in Rejection
Duato’s career with Johnson & Johnson did not begin with a successful interview. Speaking at Fortune’s CEO Initiative in 2023, he recalled applying to the company after graduate school and failing to reach the second interview.
He then accepted a position with another pharmaceutical company. Duato did not identify that employer during the conversation, but he eventually found another route into Johnson & Johnson.
The episode provides a useful starting point for his professional chronology. An unsuccessful first attempt was followed by a career at the organization that had lasted 34 years by the time of the Fortune interview. Duato credited the company’s later development opportunities, rather than that initial application, with allowing him to work across different functions and gradually assume greater responsibility.
Duato Built His Career Across Regions and Business Sectors
Joaquin Duato joined Janssen-Farmaceutica, a Johnson & Johnson subsidiary in Spain, in 1989. In a written statement presented to the U.S. Senate in February 2024, he said that he spent his first 13 years at the company in European executive positions.
His work eventually extended beyond one country or operating division. Official corporate and regulatory records document experience across different geographies, functions and business segments, including the operations currently known as Innovative Medicine and MedTech.
Duato has described this movement within the organization as central to his professional development. Instead of following a career confined to a single specialty, he acquired experience in several areas of a large healthcare company. He later referred to Johnson & Johnson as having an internal job market that allows employees to pursue different career paths without leaving the organization.
This varied background became especially relevant as his responsibilities expanded. By the time he reached senior management, he had worked with pharmaceutical operations and other parts of the company while gaining experience in both European and American healthcare markets.
His Pharmaceutical Roles Led to the Executive Committee
Duato’s progression into Johnson & Johnson’s senior leadership can be traced through several documented appointments. In 2009, he became Company Group Chairman, Pharmaceuticals. Two years later, he was named Worldwide Chairman, Pharmaceuticals.
He joined the company’s Executive Committee in 2016 when he became executive vice president and Worldwide Chairman, Pharmaceuticals. That position placed him among the executives responsible for decisions affecting the larger organization, rather than one national or regional business.
Another promotion followed in July 2018, when Duato became vice chairman of the Executive Committee. His responsibilities then covered the pharmaceutical and consumer-health sectors as well as supply chain, information technology, global services, and health and wellness operations.
The range of those duties distinguished his preparation for the CEO position from a career based exclusively in drug development or sales. He had gained exposure to commercial businesses, company-wide services, and operational systems before the board selected him for the top executive role.
Joaquin Duato Became CEO and Then Chairman
On August 19, 2021, Johnson & Johnson named Duato as Alex Gorsky’s successor for the chief executive role. The transition took effect on January 3, 2022, when Duato also joined the company’s board of directors.
The appointment made him the eighth person to lead Johnson & Johnson as CEO since the company became publicly traded. In a later Fortune interview, Duato described himself as its first CEO who was not born in the United States.
His chairmanship followed on a separate timeline. The company disclosed in November 2022 that Duato would take over from Gorsky as chairman after the transition. He assumed that additional position in January 2023.
The distinction between the two appointments is important to his career record: Duato first became CEO and a director, then added responsibility for chairing the board approximately one year later.
The Kenvue Separation Sharpened the Company’s Focus
One of the defining corporate changes associated with Duato’s early period as CEO was the separation of Johnson & Johnson’s consumer-health operation as Kenvue. That business took responsibility for familiar consumer brands, while Johnson & Johnson concentrated on medicines and medical technology.
In a 2023 interview with Fortune, Duato outlined the thinking behind the decision. Competing in consumer markets such as skincare required a different focus from developing biologic medicines and surgical technology. He said separating the operations would allow each company to concentrate more clearly on its own customers, patients and competitive environment.
Following the separation, Johnson & Johnson organized its strategy around Innovative Medicine and MedTech. Its priority areas include oncology, immunology and neuroscience in medicines, alongside cardiovascular care, surgery and vision in medical technology.
The decision involved Johnson & Johnson’s board and wider leadership team, not Duato alone. As CEO, however, he publicly presented the separation as a way to simplify the company’s mission and direct its research resources toward medical breakthroughs.
His Leadership Priorities Include Learning and Listening
Duato’s public remarks about leadership often return to professional development. In the Fortune discussion, he connected Johnson & Johnson’s employee retention with the ability to move between roles and build a long-term career inside the company.
He also spoke about company learning programs and the importance of giving employees time to develop new skills. His own movement between regions, functions and operating sectors formed the basis of that perspective.
When discussing the leadership team responsible for Kenvue, Duato said he advised its executives to maintain patience and perspective while learning to listen more. Those comments offer a direct account of the practices he considers valuable, without requiring broader assumptions about his private personality.
His prepared Senate testimony presented another part of his professional outlook. Duato said the company’s responsibilities extend both to people who need existing treatments and to future patients who depend on continued research. Because that statement was delivered during a hearing about drug prices, it represents his stated corporate position on balancing access, affordability and further innovation.
Cancer Research, Cognitive Health and AI Shape His Current Work
In a Wall Street Journal Leadership Institute interview recorded in June 2026, Duato described cancer as one of Johnson & Johnson’s central research priorities. He said the long-term objective is to cure certain cancers while turning others into chronic diseases that can be managed effectively.
He also discussed dementia and age-related cognitive decline as major social and economic concerns. For Duato, progress in longevity should not be measured solely by additional years of life. He argued that longer lives need to be accompanied by dignity, cognitive health and a good quality of life.
Artificial intelligence formed another major part of the conversation. Duato called AI a force multiplier for life-sciences companies because of its potential to help researchers develop medicines and medical technologies faster and more effectively.
The company’s official biography also notes Duato’s support for combining AI with professional expertise. These remarks describe the company’s present direction and Duato’s expectations for the technology; the medical outcomes he discussed remain long-term objectives rather than completed results.
His Verified Leadership Work in 2026
Duato remained active as Johnson & Johnson’s chairman and CEO throughout 2026. In January, the company announced an agreement with the U.S. government concerning access to medicines and pricing. It also outlined continued progress toward a planned $55 billion investment in American manufacturing, research, development and technology through early 2029.
The company expanded those plans in February by announcing more than $1 billion for a next-generation cell-therapy manufacturing facility in Montgomery County, Pennsylvania. The project was presented as part of Johnson & Johnson’s broader effort to increase advanced medicine production in the United States.
Corporate filings published in March documented Duato’s compensation for his 2025 performance. Johnson & Johnson reported $27.142 million in total direct compensation and increased his base-salary rate from $1.6 million in 2025 to $1.75 million for 2026. A broader summary-compensation calculation reached approximately $32.8 million because it included additional accounting categories. Neither amount represents an estimate of his personal net worth.
Johnson & Johnson recorded $25.31 billion in second-quarter sales and increased its annual forecast in July 2026. Duato said the company was on course to exceed $100 billion in annual revenue for the first time, although that statement remained a projection rather than a completed full-year result.
What Joaquin Duato’s Career Progression Shows
Joaquin Duato’s verified professional history follows a clear path from Janssen-Farmaceutica in Spain to the chairmanship and CEO position at Johnson & Johnson. Between those points, he accumulated experience in European operations, pharmaceuticals, consumer health, medical technology, and company-wide services.
His first unsuccessful application adds an unusual but directly confirmed beginning to that chronology. Once inside the company, he advanced through international and cross-sector assignments before joining the Executive Committee, becoming vice chairman and eventually succeeding Alex Gorsky.
Duato’s current public work centers on a more focused Johnson & Johnson built around medicines and medical technology. Cancer research, cognitive health, AI and U.S. manufacturing investment now feature prominently in his stated priorities. His documented career is defined by corporate advancement, international experience and an increasing focus on healthcare innovation.